Zarxio (Filgrastim-sndz) for Breast Cancer

Overview
Zarxio is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat febrile neutropenia (a lack of white blood cells, plus fever). If you have neutropenia caused by chemotherapy for breast cancer, your doctor may prescribe Zarxio. Zarxio is also referred to by its drug name, filgrastim-sndz.

Zarxio is a biosimilar, or a drug designed to have similar active properties as an existing drug. In the case of Zarxio, it is designed to have similar active properties as Neupogen. Neupogen is a biologic drug and a colony stimulating factor, or substance that induces the bone marrow to produce more white blood cells. Neupogen is believed to work by stimulating the production of white blood cells, which fight infection and fever.

How do I take it?
Prescribing information states that Zarxio should be administered once a day via a subcutaneous injection, intravenous injection, or intravenous infusion.

Zarxio comes as a prefilled syringe.

Side effects
The FDA-approved label for Zarxio lists common side effects including fever, pain, rash, cough, and difficulty breathing.

Rare but serious side effects listed for Zarxio can include systemic allergic reactions, fatal sickle cell crises, low blood cell counts, kidney problems, acute respiratory distress, and rupture of the spleen.

For more information about this treatment, visit:

Zarxio — Sandoz
https://www.zarxio.com/patient